Monthly Archives: January 2010

BUSINESS WIRE: MPI Research is taking the initiative in response to new FDA directive Abuse potential for medicines

COMMUNICATION Business Wire, Sept. FOR THE CONTENT IS
ALONE
Business Editors THE REPORT.

-------------------------------------------------- ----------------------



Mattawan, Michigan (USA) - (BUSINESS WIRE) - 31.01.2010 --

Published on January 26, 2010
U.S. Agency for Food and
Drug safety FDA (Food and Drug Administration) a
important
Draft Guideline for assessment of
Potential for abuse in
Medicinal products ( "Guidance for Industry Assessment of Abuse
Potential of Drugs ").
In its current form to guide the current position is
the FDA in
Regarding the abuse potential of drugs to play.
Noteworthy
is in the draft that the industry guideline S7A (471,
safety pharmacology studies of drugs for
People) and in the
FDA Regulation 21 CFR 472, Section 58, required good
Laboratory Practices
(GAP) now also for animal studies of abuse potential
. are

As the only contract research organization in the world with
all
Testing services to addictive potential, both in rodents
as well as
Primates fully GLP compliant, recognizes MPI
Research the
Publication of this draft guidance. The Company
was already in the
Past, an active supporter of the FDA's recommendations
between 1981 and 1999,
which is a preferred application of GLP standards during
routine
Implementation of these types of studies confirmed
(see FDA publication
"Guidance for Industry Good Laboratory Practice Questions and
Answers "), and it
welcomes this important measure of
Inspectorate.

The Suchtpotenzialprogramm at MPI Research, which from a
leading expert
conducted in this field (David Gauvin, PhD,
Chief Scientist
the Department of Neurological conditional behavior),
used currently four
of the five tests that are mentioned in these guidelines:
Self-medication,
Distinction of drugs, assessment of
psychomotor activity
and dependence potential. The company is
currently in the process, the
GLP-validation of the test for conditioned preference
a place to
gain and is with this last point later this year, all
five tests
can offer. Dr. Gauvin hints that "the goal
and the continued
Focus of MPI Research is fully GLP compliant
and validated
Nuclear batteries provide estimates that are both
the abuse as
also the dependence potential of new chemical
Compositions
adequately address, so that the official
Litmus test in both
Relation to drug control as well as the
Drug safety evaluation exist, what the
Submission of a
Application for admission for a new drug is a condition.
Compliance with the
GLP helps us in ensuring the highest
Quality in non-clinical
Laboratory tests for evaluating the
authorities in conformity with standards
new products for both international as well as for
National
Safety and for
Medicines Control rules
are required. "

Ted Baird, PhD, Head of the Departments of
Safety pharmacology and
neurologically conditioned behavior, adds that "MPI
Research as
proven leading institute for
Such safety pharmacology
Anticipate developments in our Department tries to
Initiatives by
promotion, as a validation of predictive tests, such as
in the
Current treatment guidelines actively promote. We
appreciate insights
the result of interactions with our colleagues within the
Industry
be obtained, and welcome future
Opportunities for collaboration
to promote our knowledge at the same time
Fulfillment of the
Research needs of our clients. "

MPI Research in Mattawan, headquartered in the U.S. state of Michigan offers
Biopharma,
medical technology, the animal and the chemical industry
Services in the areas of development,
Safety evaluation
Bioanalysis and analysis on. Scientific knowledge and
Experience
Integrity, trust, teamwork and commitment to
close and continuing
Relationships with clients are qualities that MPI Research
than
performance and quality-focused organization
distinguished, which
for greater safety and efficacy of new products on the
Market begins.
Learn more about how we exceed your expectations
can, see
http://www.mpiresearch.com/.

Photos / Multimedia Gallery:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid =
6161151 & lang = en

The original language of the original text
is published, the
official and authorized version. Translations
will help in better
Understanding included. Only the
Language, the original
has been published, or otherwise. Equal to
Thus Translations
with the original language of publication
off.

[CT]

Contact:
MPI Research
William Harrison, COO
(269) 668-3336
William.harrison @ mpiresearch.com

BUSINESS WIRE: Gilead Sciences announces record financial results for fourth-quarter and full year 2009 announced Part_1 / 2

COMMUNICATION Business Wire, Sept. FOR THE CONTENT IS
ALONE
Business Editors THE REPORT.

-------------------------------------------------- ----------------------

- Total annual revenues of 7.01 billion U.S. dollars,
Increase by 31 percent
compared to 2008 --

- Product sales for the full year of 6.47 billion
U.S. dollars, increasing by 27
Percent over 2008 --

- Earnings per share for the fourth quarter non-GAAP basis of
$ 0.93
per share increased by 49 percent from the fourth
Quarter of 2008 --

- Earnings per share for the full year to non-GAAP basis, of 3.06
U.S. Dollar per
Share, up 40 percent over 2008 --

FOSTER CITY, California (USA) - (BUSINESS WIRE) - 31.01.2010 --

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its
Operating results for the
fourth quarter and full year 2009 announced.

The total amount of revenue in the fourth quarter of 2009 amounted to
2.03 billion
U.S. dollars, an increase of 42 percent over the
Total income
equivalent of 1.43 billion U.S. dollars in the fourth quarter of 2008.
The
Net income for the fourth quarter of 2009 amounted to 802.2 million
U.S. Dollar
or 0.87 U.S. dollars per diluted share
compared to a
Net income for the fourth quarter of 2008 from 560 million
or 0.59
U.S. Dollar per diluted share. The
Non-GAAP net income for the fourth quarter
2009, the übernahmebezogenen transaction costs, which
Restructuring costs and the share -
Compensation expense for
Does not include taxes, amounted to 864.4 million
or 0.93
U.S. Dollar per diluted share. The
Non-GAAP net income for the fourth quarter
2008, as the share-based compensation expense after tax
does not include,
amounted to 590.3 million or $ 0.63 per
diluted share.

The total annual revenue in 2009 totaled 7.01 billion
U.S. dollars, an
Increase of 31 percent over the
Total annual revenues of 5.34
Billion U.S. dollars in 2008 corresponds. Net income for the
FY
2009 amounted to 2.64 billion dollars or 2.82 per
diluted
Share, versus a net profit of 1.98 billion
or 2.06
U.S. Dollar per diluted share for the full year 2008. The
Non-GAAP net income
for full year 2009, the übernahmebezogenen
Transaction costs for
Taxes, restructuring costs and the share -
Does not include compensation expense, was 2.86
Billion U.S. dollars
or 3.06 per diluted share. The
Non-GAAP net income for the
Total annual 2008, as the share -
Compensation expense and the cost of
acquired know-how from research and development not
includes amounted
2,10 billion and as 2.19 U.S. dollars per
diluted share.

Product sales

Product sales increased by 30 percent to a
Record high of 1.80
Billion U.S. dollars in the fourth quarter of 2009 compared with 1.39
Billion
U.S. dollar in the fourth quarter of 2008. 2009 increased the
Product sales
Compared to the year 2008 by 27 percent to 6.47 billion
U.S. Dollar. Drive
for the increase was primarily the Antiviral Franchise
Gilead
including the strong growth of sales of
^ Atripla ® (efavirenz 600
mg / emtricitabine 200 mg / tenofovir disoproxil fumarate 300 mg) and
that
continued growth in sales of Truvada ® ^
(Emtricitabine and tenofovir
Disoproxil fumarate).

Antiviral Division

Revenues increased by Antiviralprodukten
27 percent to 1.62 million
U.S. dollar in the fourth quarter of 2009 compared with 1.27 billion
U.S. Dollar in
fourth quarter of 2008, mainly driven by the
Growth
Sales volumes of Atripla and Truvada. 2009 rose
Product sales in
Antiviralprodukten by 25 percent to 5.84 billion U.S. Dollar
compared to 4.67
Billion U.S. dollars in 2008, mainly driven
by
Sales volumes of Atripla and Truvada, and partially offset
through
adverse Wechselkursschwankungen.   * Atripla

Sales of Atripla rose 50 percent to 697.8
Million U.S. dollars
in the fourth quarter of 2009 compared to 465.5 million U.S. Dollar
fourth quarter
2008 and the first time surpassed the sales of Truvada.
2009 increased the
Atripla sales increased by 51 percent to 2.38 billion U.S. Dollar
compared to 1.57
Billion U.S. dollars in 2008. The increase in
Truvada sales in the
fourth quarter and full year 2009 compared with the
Comparable periods of
2008 goes mainly to the growth of sales volumes
in the U.S. and
Europe back.   * Truvada

Sales of Truvada rose 19 percent to 670.7
Million U.S. dollars
in the fourth quarter of 2009 compared to 562.1 million U.S. Dollar
fourth quarter
2008th In 2009, sales increased by 18 Truvada
Of 2.11 percent
Billion U.S. dollars in 2008 to 2.49 billion U.S. dollars. The
Increase
Truvada sales in the fourth quarter and full year 2009
against
Comparable periods of 2008 goes on mainly
growth
Sales volumes back in the U.S. and Europe.   * Viread

^ ®, sales of Viread (tenofovir disoproxil fumarate)
increased by ten
Percent to 178.3 million U.S. dollars in the fourth quarter of 2009
compared to 161.9
Million U.S. dollars in the fourth quarter of 2008. 2009 increased
The turnover
Viread by seven percent to 667.5 million U.S. Dollar
compared to 621.2
Million U.S. dollars in 2008. The increase in
Viread sales in the fourth
Quarter and full year 2009 compared to the
Comparable periods of 2008 goes
mainly on the growth of sales volumes
Viread for the
Treatment of the hepatitis B virus (HBV) infected
Patients in the U.S.
Europe and back.

Letairis

Revenue Letairis ^ ® (ambrisentan) for the treatment
pulmonary arterial
Hypertension in the fourth quarter of 2009 increased by 44 percent
to 52.2
Million compared to $ 36.2 million in the fourth
Quarter of 2008. 2009
to increased sales of Letairis by 63 percent to 183.9
Million
U.S. Dollar compared to 112.9 million in 2008. The
Increase
Letairis sales in the fourth quarter and full year 2009
against
Comparable periods of 2008 goes on mainly
growth
Sales volumes back into the United States.

Ranexa

Sales of ^ Ranexa ® (ranolazine) for the treatment
chronic angina were
in the fourth quarter of 2009 46.0 million U.S. dollars respectively
131.1
Million after the acquisition of CV Therapeutics, Inc. (CV
Therapeutics) by
Gilead, 15 April 2009.

Other products

Revenues ^ AmBisome ® (amphotericin B liposome for
Injection), Hepsera ® ^
(Adefovir dipivoxil), ^ ® Emtriva (emtricitabine) and other
Products was
in the fourth quarter of 2009 159.5 million U.S. dollar against
162.1 million in
fourth quarter of 2008 and 615 million U.S. dollars in FY
2009 compared with
671.6 million U.S. dollars in the full year 2008.

Licensing, contract and other revenues

Licensing, contract and others are mainly from the
Cooperation with
Business partners resulting income was in the fourth
Quarter of 2009 228
Million U.S. dollars, an increase of 40.4 million
compared with the
fourth quarter of 2008 corresponds. In 2009, increased the
Licensing,
Contract and other revenues by 116 percent from 251 million
U.S. Dollar in
In 2008 to 542.1 million. The increase was
largely due to the higher
^ Royalties on Tamiflu ® (oseltamivir
Phosphate) by F. Hoffmann-La Roche
Ltd. in the amount of 194.1 million and 392.7 million U.S. dollars in
fourth
Quarter and full year 2009 return, compared with the
Tamiflu royalties in the fourth quarter and full year
2008 of 16
Million U.S. dollars or 155.5 million, and had
originate
in the increased sales associated with
global
Pandemic preparedness activities.

Research and Development

Spending on research and development in the fourth quarter
2009 amounted tos
239.6 million U.S. dollars compared to 201.9 million in
fourth quarter 2008.
The non-GAAP expenses for research and development in
fourth quarter of 2009,
neither share nor restructuring costs
Compensation expense
included, amounted to 211.3 million U.S. dollars in contrast to the
185.3
Million in the fourth quarter of 2008, which do not share
Compensation expense included. This increase was
mainly on the
larger workforce and the cost of
Support for Enhanced
Research and development activities from Gilead
back. 2009 amounted to
Spending on research and development 939.9 million
U.S. Dollar in comparison
to 721.8 million in 2008. The non-GAAP expenses for
Research and
Development, restructuring costs not yet
share
Compensation expense included, amounted in 2009 831.3
Million U.S. dollars in
Contrary to the 655.2 million U.S. dollars in 2008, not the
share-based compensation expense included. This
Increase was
mainly due to the larger workforce
and the cost to support
the advanced research and development activities
Gilead and on
the reimbursement of research and development expenditure
Context, the
Collaboration with Tibotec Pharmaceuticals, Gilead
back.

Sales, administrative and general

The expenditure to cover the sales, general and administrative
Overheads
were in the fourth quarter of 2009 253.9 million U.S. dollars
compared to 193.7
Million U.S. dollars in the fourth quarter of 2008. The
Non-GAAP expenses for
Cover the sales, administrative and general expenses in the fourth
Quarter
2009, neither transaction costs nor übernahmebezogene
Restructuring costs and share -
Compensation expense included
amounted to 223.4 million U.S. dollars as opposed to 174.7
Million
U.S. Dollar in the same period in 2008, not the
share
Compensation expense included. 2009 was spent
for sale,
Administrative and general expenses 946.7 million U.S. dollars in
Compared to
797.3 million U.S. dollars in 2008. The non-GAAP expenses for the
Cover
Sales, general and administrative overheads that do not
übernahmebezogene
Transaction costs or restructuring costs or
share
Compensation expense included, amounted in 2009 820.1
Million U.S. dollars in
Contrary to the 720.8 million U.S. dollars in 2008, not the
share-based compensation expense included. The
Increase
Non-GAAP to cover the administrative expenses of sale, and
Overheads
in the fourth quarter and full year 2009 was driven primarily by
on the larger
Staffing and costs to support the
advanced
Business back.

Income taxes

The effective tax rate in 2009 was 25 percent compared
to 26.3
Percent in 2008. The reduction in the effective tax rate
for 2009
was based primarily on increased yields in areas with
lower tax rates
as well as on the completion of certain tax audits
Tax authorities,
partially offset by the revaluation of certain tax assets in
State in
Related to the integration of CV Therapeutics outweighed
were. The
Tax rate in the fourth quarter of 2009 amounted to 24.6 percent.

Net effect of exchange rates

The net impact of exchange rates on revenue and
Income before
Taxes in the fourth quarter of 2009, including
generated outside the U.S.
Revenue and expenditure, was a favorable 13.8 million
U.S. Dollar
or 8.6 million U.S. dollars compared to the fourth
Quarter
2008th The impact on revenue and income before tax
of 2009
were $ 98.5 million unfavorable U.S. dollar
or 33.6 million
U.S. Dollar compared to 2008.

Cash, cash equivalents and securities holdings

The deadline of 31 December 2009 ordered Gilead
cash,
Cash equivalents and securities holdings from 3.9 billion
U.S. dollar against
3.24 billion U.S. dollars on 31 December 2008. Gilead
generated in
2009, a cash flow from operating activities
from 3.08 billion
U.S. dollars, of which 955.3 million U.S. dollars in the fourth quarter of 2009.

Existing and products under development

Antiviral Division

In October, Gilead announced the presentation of data from two
three
(144-week) open label phase of the pivotal trials
III, Studies 102
and 103, an. They relate to the investigation of the safety and
Efficiency of once-daily regimen of Viread in
adult patients with
chronic hepatitis B infection (HBV). These data were
during
annual conference of the American Association for the Study of
Liver Diseases
presented in Boston.

In November, gave Gilead and GlaxoSmithKline (GSK) a
Agreement on
Marketing of Viread for the Treatment of Chronic
HBV infection in
Known adults in five countries in Asia.
Under the agreement reserves
Gilead's Viread for the exclusive marketing rights against HBV
in Hong Kong,
Singapore, South Korea and Taiwan. In China, GSK is the exclusive
Marketing rights and the responsibility for approving
Viread against HBV
have. Each company will be the other royalties
for the sale of
Viread against HBV in their respective contract areas in Asia
. pay The
Companies are committed to this agreement to Japan and other
Countries
expand.

Cardiovascular Division

In November, in collaboration with GSK, Gilead announced plans for
an international,
(in terms of morbidity and mortality)
event-driven clinical trial
to investigate the combination therapy compared to
Monotherapy in
Primary care from PAH. As part of the study, AMBITION (a
randomized, double-blind, multicenter study to
Initial treatment with
Ambrisentan and tadalafil as a combination therapy
Test subjects with PAH),
is the combined use of ambrisentan, an
Endothelin receptor antagonist (ERA), and tadalafil, a
PDE5 inhibitor
be investigated in the initial treatment of patients with PAH.

In December, Gilead announced that the DAR-312, a clinical trial
Phase
III for the study of darusentan, the ERA of the company to
Treatment
resistant hypertension, their two primary
Efficacy endpoints for the
Changes in systolic blood pressure value and lowest
the lowest
diastolic blood pressure values within 14 weeks compared
to placebo
has not been achieved. Given this result has been the
Company
decided to treat the development of darusentan
not to pursue intractable hypertension.

Respiratory Division

In December, recommended that the Anti-Infective Drugs Advisory Committee of the
U.S. Agency for Food and
Drugs, the U. S. Food and
Drug Administration (FDA) that aztreonam as
Inhalation solution to treat
of infections due to Pseudomonas aeruginosa in patients
with
Cystic fibrosis should be allowed. The committee voted 15 to
2 In
From that Gilead sufficient evidence of safety and
Efficacy of
Aztreonam has taught as an inhalation solution. The
Committee voted on
as to 17 to 0 from above, that as aztreonam
Inhalation Solution 75 mg three times
daily is the correct dosage and treatment. The
Recommendations
Committee are not binding, will be approved by the FDA, but
considered
if that their examination of the application for drug approval
Gilead, whose
Date referred to Prescription Drug User Fee Act of the 13th
February 2010ist,
concludes.

Conference Call

Today at 4:30 PM Eastern Time, the Board will
Gilead one
Conference call and simultaneous webcast to
Discuss
Results for the fourth quarter and full year 2009
and organize
while in general about the current state of
Shops report. To
live on the Internet have access to the webcast,
please call
at least 15 minutes before the start of the conference call, the website
of
Company on at www.gilead.com to ensure that
You have enough
Time for downloading if needed
Software for listening to the
Webcasts have. Alternatively, please call the number
1-800-901-5226 (within
the U.S.) or 1-617-786-4513 (international) and to
enter the
Access keys 28771667 one, to gain access to the conference
preserved.

A replay of the webcast will be a on the company website
Year
be available. A telephone replay will be about two
Hours after
Conference until Friday 29 January 2010 is available
stand. The
Telephone replay is available under the number 1-888-286-8010
(within the
USA) or 1-617-801-6888 (international) available;
the
Access key is 47,805,358th

About Gilead

Gilead Sciences is a biopharmaceutical company that develops
Medicinal
Fields of unmet medical needs, discovers, develops and
commercialized.
Gilead has made it his business to supply
fatal
diseased patients worldwide push. Gilead has its
Headquartered in
Foster City, California, USA and has subsidiaries
in
North America, Europe and Australia.

Non-GAAP Financial Information

Gilead is certain financial information for the fourth
Quarter and
Full year in accordance with GAAP (generally
recognized
Accounting principles of the United States) and also to
Non-GAAP dar. The
Management believes that these non-GAAP information for
Investors
provide benefits when read together with the GAAP financial statements of
Gilead
be considered, since management such information internally
for industrial,
Budgeting and financial planning purposes uses.
Non-GAAP information is not
in the context of a comprehensive rules and regulations on accounting
and processed
should only supplement the understanding of
Operating results of Gilead --
as they are reported under U.S. GAAP - used
will. A
Reconciliation between GAAP and
Non-GAAP financial information is in the
Table shown on page 7.

Forward-Looking Statements

Statements in this press release that are not on historical
Facts
relate, are "forward-looking statements" within the meaning
of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that
that
forward-looking statements involve risks and uncertainties
subject to the
could cause the actual
Results to which
vary. These risks and uncertainties: the
Ability
Gilead, the revenue growth of its divisions and antiviral
Cardiovascular
Products to maintain, unpredictable variations in the
License revenues from Tamiflu and the close relationship of these
License revenue with
global arrangements and deliveries in relation to pandemics, the
Ability
Gilead, timely or at all
regulatory approvals for
new and existing products, such as for aztreonam
Inhalation Solution in
the United States and to receive Viread for HBV in Asia and the
Ability
Gilead, its franchise areas of respiratory and
Cardiovascular
Successfully develop products, the fact that the beginning and
Completion
clinical trials may take longer or cost more than
expected to
includes the clinical trial to investigate
Ambrisentan and tadalafil
in patients with pulmonary arterial hypertension, fluctuations in exchange rates
against the U.S. dollar,
The favorable influence of the courses for future
Revenues or profits from
Taxes reduce or destroy, as well as other risks
each in
The Gilead with the U.S. Securities and Exchange Commission (Securities and
Exchange Commission)
submitted reports be given. Furthermore
Gilead takes
Estimates and evaluations prior to the stated totals 
of assets,
Liabilities, revenue and expenditure and the associated information
concern. Gilead
bases its estimates on experience from
Past and on
several other market-specific and other relevant
Assumptions under
the circumstances are considered appropriate. These
Results are
the basis for assessing the carrying values of those assets
and liabilities
not clearly emerge from other sources. The
Actual results
may differ materially from these estimates.

You are urged to consider statements that contain the words
"May," "will", "would",
"Could," "should,"
"May," "believe," "estimate,"
"Anticipate",
"Potential," "expect",
"Plan", "intend" continue, "",
Predict, "" targeted "
"Target" or the respective negative
of these words or other comparable words
included as unsafe and
to be considered forward-looking statements. Gilead directs the
Readers to its
Annual Report on Form 10-K for the year ended 31 December 2008
year ended,
its quarterly reports on Form 10-Q for the first
second and third
Quarter of 2009 and its subsequent current reports on
Form
8-K. Gilead claimed protection under the
Safe Harbor Statement under
Private Securities Litigation Reform Act of 1995 for
forward
Statements. All forward-looking statements are based on the Gilead
present
information available and the company assumes
no obligation
to update any such forward-looking statements.

Truvada, Viread, Hepsera, AmBisome, Letairis and are Ranexa
registered
Trademarks of Gilead Sciences, Inc.

Atripla is a registered trademark of Bristol-Myers Squibb &
Gilead Sciences,
LLC.

Tamiflu is a registered trademark of F. Hoffmann-La Roche
Ltd..

For more information on Gilead Sciences, Inc., please visit
under
www.gilead.com or call for the Department of
Promotion of
Gilead at 1-800-GILEAD-5 (1-800-445-3235).

GILEAD SCIENCES, INC..
CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT
(unaudited)
(in thousands) except per share data

Dreimonatszeitrum ended the year                            to
31. December 31 December
2009 2008 2009 2008

Income:
Product sales $ 1,804,398 $ 1,387,772 $ 6,469,311 $
5,084,796
License, contract-227,981 40,433
542,072 250,954     and other revenues
Total income 2,032,379 1,428,205
7,011,383 5,335,750
Costs and expenses
Cost of sales 473,399 321,531 1,595,558 1,127,246
Research and 239,645 201,863 939,918 721,768     Development
Sale,
And administrative 253,897 193,665 946,686 797,344     Overheads
Acquired know-how
from research and - - --
10,851     Development
Total costs and 966,941 717,059
3,482,162 2,657,209
Expenditure
Operating income 1,065,438 711,146 3,529,221 2,678,541
Interest and other 11,299 19,038 42,397 59,401
Income, net
Interest expense (1) (17,290) (16,433)
(69,662) (65,244)
Income before
Provisions for 1,059,447 713,751 3,501,956
2,672,698
Income taxes
Accrued 260,054 156,157
876,364 702,363
Income taxes (1)
Net income (2) 799,393 557,594 2,625,592 1,970,335
Pro rata net loss
from 2,819 2,369 10,163
8,564
Minority interests
(2)
Pro rata net loss $ 802,212 $ 559,963 $
2,635,755 $ 1,978,899
Gilead (2)
Pro rata net profit
per share of $ 0.89 $ 0.61 $ 2.91 $ 2.15
Gilead common stock --
Base set (2)
Pro rata net profit
per share of $ 0.87 $ 0.59 $ 2.82 $ 2.06
Gilead common stock --
Diluted (2)
Number of shares for
Calculating per share - 899,829 911,168
904,604 920,693
Basic stock
Number of shares for
Calculating per share - 926,913 942,837
934,109 958,825
diluted

Notes:

On 1 Gilead's application in January 2009 led to the guideline
Issue debt
FASB ASC (formerly FSP APB 14-1) retroactively to his
convertible senior notes
one and reflected in additional interest expense after tax
from 8.7 million
(1) U.S. dollars or 8.2 million U.S. dollars for the
Three-month periods,
at 31 December 2009 and 2008 ended up against, and
reflected
additional interest expense after tax of 34.3 million
U.S. Dollar
or 32.3 million U.S. dollars for the
Nine-month periods, the most     31. December 2009 and 2008 ended up against.

On 1 Gilead's application in January 2009 led to the guideline
Topic
Consolidation of the FASB ASC (the old SFAS 160) and reported
retrospectively
(2) its minority interests ( "noncontrolling
interest ", formerly" minority
interest ") as a share of net loss of
Minority interests, which is a     Part of the consolidated net profit is.      GILEAD SCIENCES, INC..
BALANCE BETWEEN GAAP AND NON-GAAP FINANZMASSGABEN
(unaudited)
(In thousands, except for figures in percent or per share)

Dreimonatszeitrum with year-end                                         End for
31. December 31 December
2009 2008 2009 2008

Reconciliation of Cost of sales:
GAAP Cost of sales $ 473,399 $ 321,531 $ 1,595,558 $ 1,127,246
Übernahmebezogene Amortization of (5,013) - (13,646) --
The stock increase
Übernahmebezogene amortization of (14,480) - (41,131) --
intangible assets
Share-based compensation expense (2,373)
(3,178) (10,859) (10,312)
Non-GAAP Cost of sales $ 451,533 $ 318,353 $
1,529,922 $ 1,116,934

Reconciliation
Product gross margin:
GAAP product gross margin 73.8% 77.2% 75.4% 78.2%
Übernahmebezogene amortization at 0.3% - 0.2% --
The stock increase
Übernahmebezogene depreciation of 0.8% - 0.6% --
intangible assets
Share-based compensation expense 0.1% 0.2%
0.2% 0.2%
Non-GAAP product gross margin 75.0% 77.4%
76.4% 78.4%

Reconciliation of expenditure
Research and Development
Spending on research and $ 239,645 $ 201,863 $ 939,918 $
721,768
Development on a GAAP basis
Restructuring expenses (8,687) - (25,718) --
Share-based compensation expense (19,701)
(16,578) (82,893) (66,523)
Spending on research and $ 211,257 $ 185,285 $
831,307 $ 655,245
Development on non-GAAP basis

Reconciliation of sales,
Administrative and general
Sales, general and administrative $ 253,897 $ 193,665 $ 946,686 $ 797,344
Overhead on a GAAP basis
Übernahmebezogene transaction costs (30) - (8,434) --
Restructuring expenses (10,689) - (26,167) --
Share-based compensation expense (19,751)
(19,003) (92,006) (76,529)
Sales, general and administrative $ 223,427 $ 174,662 $
820,079 $ 720,815
Overheads on non-GAAP basis                                                Part_1 / 2

BUSINESS WIRE: Tesla submit a registration statement

COMMUNICATION Business Wire, Sept. FOR THE CONTENT IS
ALONE
Business Editors THE REPORT.

-------------------------------------------------- ----------------------



PALO ALTO, California (USA) - (BUSINESS WIRE) - 31.01.2010 --

The company Tesla Motors Inc. announced today the filing of the
Form S-1
with the U.S. Securities and Exchange Commission
because of an application for
Listing for the proposed offering of
Common shares announced
given. Tesla Motors designs, manufactures and sells
powerful
all-electric vehicles, and components of the powertrain
for
Electric vehicles. The number of shares to be issued and their
Price ranges are
not yet been determined.

Goldman, Sachs & Co., Morgan Stanley, J.P. Morgan and German
Bank Securities
acting as bookrunner for the issue together.

As soon as the preliminary prospectus may
this in the following
Jobs are available: Goldman, Sachs & Co., Tel: (866)
471-2526, fax: (212)
902-9316, E-mail: prospectus-ny@ny.email.gs.com,
Address: Goldman, Sachs
& Co., Attn: Prospectus Department, 85 Broad Street, New
York, NY 10004;
Morgan Stanley & Co. Incorporated, Phone: (866) 718-1649;
E-mail:
prospectus@morganstanley.com, postal address: Morgan Stanley
& Co. Incorporated,
180 Varick Street, New York, NY 10014, attn: Prospectus
Department; J.P.
Morgan Securities Inc., Tel (toll free in the U.S.):
1-866-803-9204,
Postal address: Broadridge Financial Solutions, 1155 Long Iceland
Avenue
Edgewood, New York, 11,717; German Bank Securities Inc., Tel: (800)
503-4611,
Address: 100 Plaza One, Jersey City, New Jersey 07311,
Att Prospectus
Department.

A registration statement relating to these
Securities is on
the SEC filed but not yet approved. These
Securities may
be sold nor may offers to buy be accepted,
before
Listing application has been approved. These
Media release does not constitute an
Offer to sell nor a solicitation to constitute an offer to purchase and
these
Securities will be sold in any state in which such
Quote,
Solicitation or sale to a corresponding
Approval or
Authorization required by applicable securities laws
would be unlawful.

The original language of the original text
is published, the
official and authorized version. Translations
will help in better
Understanding included. Only the
Language, the original
has been published, or otherwise. Equal to
Thus Translations
with the original language of publication
off.

[CT]

Contact:
Tesla Motors, Inc.
Khobi Brooklyn, 650-701-2890

WEEKEND OVERVIEW – 30 and 31 January 2010

Eddy stolen records
According to the Liechtenstein affair two years ago, there are again Eddy stolen records. As the newspaper "Frankfurter Allgemeine Zeitung (FAZ / Saturday edition) reports, then a Informant of the German tax data from 1,500 investors offered to have their money may pass on tax in Switzerland have created. The man asking for 2.5 million euros. Federal Finance Minister Wolfgang Schäuble (CDU) considered the report says now whether he should engage in trade.
Swiss Bankers Association warns Germany against data purchase
The umbrella organization of Swiss banks (Swiss Bankers Association), Germany prior to a purchase of stolen records warned. If it is in fact, be a data theft, we expect the German government that it is not the fence of Stolen property does, but returns the data to the owner and against the thief criminal proceeds, "it says in a most Weekend on the website of the Swiss Communication Bankers Association.
EU sees euro by Greece at risk – SZ
The European Commission sees the Common currency euro by the dire financial situation in Greece endangered. The economic situation there was "long-term risky, "says a draft of a memorandum of European Council in Greece, which should be adopted in February and The "Süddeutsche Zeitung" (SZ / Saturday Edition) present. The economic and financial situation of Greece could "negative impact on other euro countries.
Coalition against euro loan for Greece – BamS
The black-yellow coalition rejects financial aid for From Greece. "There will be no euro bond. The German Taxpayer is not liable for the spending of other governments, " FDP said budget expert Otto Fricke of the newspaper "Bild am Sunday "(Bild am Sonntag). The Union is opposed to loans from the other euro countries for Greece from.
Kauder urges financial transaction tax
The Union urges more emphasis on Financial transaction tax. "We need a worldwide Financial transaction tax, "said the chairman of the CDU / CSU parliamentary group, Volker Kauder, in an interview with the magazine "Focus", according to a Preliminary report from the weekend.
Commerzbank plans to expand SME Business – EAMS
Commerzbank plans to expand its SME business and particularly the regional banks, savings banks and Raiffeisen banks shares wheel flange. "We are to focus mainly on those companies that their International business and want to expand, "said Commerzbank Corporate Board Member Markus Beumer talking to the business paper "Euro am Sonntag" (EAMS). "Since the state banks, and more withdraw more from the export, is waiting for us additional business potential. In the medium term we are the market share in the SME business further increase, "he added.
Opel’s supervisory board warns of state assistance – Daily Mirror
The plans of the U.S. car group General Motors (GM) to Renovation of Opel should not be considered by the IG Metall Tax dollars are supporting. "These plans should it be no state assistance, "said Armin Schild of the Opel Supervisory Board Newspaper Tagesspiegel am Sonntag. "The recent GM’s plan is worse than anything that had submitted what Magna " said the head of IG Metall Frankfurt district added. In addition to the "excessive downsizing" shield especially criticized the lack of Future investments in new drives and new markets.
Change in the Supervisory Board of Porsche
The new Porsche shareholder has a seat in Qatar Supervisory Board of the sports car maker will receive. The general meeting of Porsche Automobile Holding SE on Friday Sheikh Abdulaziz Bin Jassim Bin Jassim Al-Thani, representing the Qatar Holding LLC in the Supervisory Board chosen as Porsche announced on Friday evening. The 31-year-old takes the seat of former board member Hans-Peter Porsche one, which his office at the end of the Annual General Meeting has resigned.
Kloeckner & Co sees slight upturn in business – EAMS
The steel trading company Klöckner & Co sees light Signs of stabilization of the business. "We are confident that we, even without the reduction achieved by the antitrust fine November in the second half of 2009, a balanced operating result to Have achieved EBITDA basis, "said CEO Gisbert Ruehl in an interview with the "Euro am Sonntag. Contrary initial fears were amortization of the inventory because of the recovery in prices at the end was not necessary.
HSBC wants majority stake in Chinese bank – Press
The financial institution HSBC Holdings plc intends this year to a Newspaper report says a majority stake in a large Chinese Bank take over. As the newspaper "Sunday Telegraph" reported is either a 51-percent stake in the Industrial and Commercial Bank of China, Bank of China and China Construction Bank Question.
WSJ: FDIC includes five other U.S. institutions
In the United States continues in the new year, the Bankensterben. The U.S. FDIC deposit insurance on Friday, five other U.S. institutions closed. The banks concerned are the Community Bank & Trust and the First National Bank of Georgia in the U.S. state of Georgia. In addition, the Community Bank of Immokalee, Florida, the Marshall Bank in Minnesota, and the First Regional Bank of Los Angeles. Thus the FDIC 2010 has already 14 U.S. banks closed. In 2009, the FDIC had 140 banks closed down.

   
DJG / cbr
Dow Jones Newswires


January 31, 2010 11:30 ET (16:30 GMT)

Change in Supervisory Board of Porsche SE

STUTTGART (Thomson Financial) – The new major shareholder Porsche Qatar has won a seat on the board of the sports car maker. The Annual Meeting of Porsche Automobil Holding SE on Friday Sheikh Jassim Bin Abdulaziz Bin Jassim Al-Thani, representing the Qatar Holding LLC, in the Supervisory Board elected as Porsche announced on Friday evening. The 31-year-old takes the seat of former board member Hans-Peter Porsche one, which his office at the end of the Annual General Meeting has resigned.
The Qatar Holding holds through its subsidiary Qatar Holding Germany GmbH 10% of the common shares of the Stuttgart Porsche SE.

   
Website: www.porsche-se.com

DJG / cbr
Dow Jones Newswires


January 31, 2010 04:40 ET (09:40 GMT)